A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Colorectal Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +11.5
A key executive is leaving
Since Oct 14, 2026 · was worth 15, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 150 (planned)
- Started
- Jul 28, 2026
- Main results expected
- Jun 2027
- Fully finished
- Dec 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only
Measured over: 6 months
To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC
Measured over: 6 months
To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC
Measured over: 6 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT07659795 · record last updated 2026-10-26 · checked 2026-11-09 15:36 UTC